Form 4: Boundless Bio CLO Jessica Oien Granted Stock Options

Boundless Bio's Chief Legal Officer, Jessica Oien, was granted 220,000 stock options with an exercise price of $1.26, vesting over 48 months.

Summary

• Jessica Oien, Chief Legal Officer and Corporate Secretary of Boundless Bio, Inc. (BOLD), was granted 220,000 stock options.
• The transaction date for this grant was January 23, 2026.
• Each stock option has an exercise price of $1.26.
• The options vest in 48 substantially equal monthly installments, commencing on January 1, 2026.
• The first 1/48th of the stock option vests on February 1, 2026, with subsequent monthly vesting thereafter.
• The expiration date for these stock options is January 22, 2036.
• Following this transaction, Jessica Oien beneficially owns 220,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally viewed positively as it aligns management's interests with long-term shareholder value and serves as a retention mechanism. This is a routine compensation event and not indicative of immediate operational or financial performance.

Positives

• The grant of stock options to a key executive like the Chief Legal Officer aligns management's long-term interests with those of shareholders, promoting retention and performance.
• The options have a clear vesting schedule, incentivizing sustained performance over a four-year period.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an executive's equity compensation.

Management Comments

• Jessica Oien, Chief Legal Officer and Corporate Secretary, was granted 220,000 stock options as part of her compensation package.

Industry Context

The grant of stock options to executives is a standard practice across various industries, particularly in biotechnology and growth-oriented companies, to attract, retain, and incentivize key talent by linking their compensation to the company's long-term stock performance.

Comparison to Industry Standards

• The grant of stock options with a multi-year vesting schedule is a common form of executive compensation, comparable to practices at other publicly traded biotechnology companies aiming to align executive incentives with shareholder value creation.
• The exercise price of $1.26 per share is typical for options granted at or near the market price on the grant date, a standard industry practice.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact through enhanced alignment of executive incentives with long-term company performance and value creation.
• Employees (Executive): Direct positive impact through increased equity ownership and potential for future financial gain based on company stock appreciation.

Next Steps

• The stock options will continue to vest in monthly installments over the next 48 months, starting February 1, 2026.

Key Dates

Keywords

Boundless Bio, BOLD, Jessica Oien, Stock Options, Executive Compensation, Equity Grant, Chief Legal Officer, Insider Transaction